U.S. researchers found that people who received glitazones, a class of diabetes treatments, had a higher risk of developing diabetic macular edema than those who did not take the drugs. "When treating patients with DME, ophthalmologists should consider the role of the glitazone class of drugs," they said.

Full Story:

Related Summaries